Biolase announces global launch of new Waterlase® C100 All-tissue laser.
Learn more about the new Waterlase C100
The Waterlase® C100 all-tissue laser combines industry-leading Waterlase YSGG technology with excellent reliability, clinician control, operating efficiency, and flexibility in tip and accessory selection. While it offers reduced clinician controls and settings compared to the Waterlase MD™, it provides for an advanced level of clinical results and patient comfort in the full range of FDA-cleared hard and soft tissue laser procedures.
“Our overall corporate mission is to transform the practice of dentistry and to make every dental practice a Waterlase Dentistry practice,” said BIOLASE Chief Executive Officer Jake St. Philip. “Considering the broad range of clinical and cosmetic dental procedures made possible and more effective by our YSGG laser technology, offering a full range of products across the spectrum of price points should get us much closer to that goal.”
St. Philip continued, “We want to provide every dentist a laser solution that addresses the needs of his or her dental practice over time. The Waterlase MD™ is ideal for dentists with a well-established and successful practice. And now, with the introduction of the Waterlase® C100, all-tissue Waterlase Dentistry is affordable to an entire new generation of dentists and a wide range of practices that want to provide their patients with the benefits of both hard and soft tissue laser procedures, but have not been in a position to purchase our more feature-rich, high-end Waterlase MD.”
The addition of the Waterlase C100 to the product family complements the market leading Waterlase MD all-tissue laser and the highly successful ezlase™ diode soft tissue laser, and now gives BIOLASE a full range of Waterlase Dentistry solutions to meet the laser needs of almost every practice regardless of age, size or specialization.
More >
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, contact: David M. Mulder, Chief Financial Officer of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949-474-4300. |
